KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Capital Leases (2016 - 2025)

Vertex Pharmaceuticals has reported Capital Leases over the past 15 years, most recently at $111.4 million for Q1 2025.

  • Quarterly results put Capital Leases at $111.4 million for Q1 2025, down 69.18% from a year ago — trailing twelve months through Mar 2025 was $111.4 million (down 69.18% YoY), and the annual figure for FY2024 was $112.8 million, down 70.01%.
  • Capital Leases for Q1 2025 was $111.4 million at Vertex Pharmaceuticals, down from $112.8 million in the prior quarter.
  • Over the last five years, Capital Leases for VRTX hit a ceiling of $530.3 million in Q1 2021 and a floor of $111.4 million in Q1 2025.
  • Median Capital Leases over the past 5 years was $417.6 million (2023), compared with a mean of $386.1 million.
  • Biggest five-year swings in Capital Leases: rose 0.55% in 2021 and later crashed 70.79% in 2024.
  • Vertex Pharmaceuticals' Capital Leases stood at $509.8 million in 2021, then dropped by 15.5% to $430.8 million in 2022, then fell by 12.7% to $376.1 million in 2023, then tumbled by 70.01% to $112.8 million in 2024, then dropped by 1.24% to $111.4 million in 2025.
  • The last three reported values for Capital Leases were $111.4 million (Q1 2025), $112.8 million (Q4 2024), and $114.0 million (Q3 2024) per Business Quant data.